| Revision as of 23:19, 22 May 2018 editLittleolive oil (talk | contribs)Extended confirmed users, Pending changes reviewers25,080 edits adjust term... transfusion is a kind of transfer← Previous edit | Revision as of 23:20, 22 May 2018 edit undoJytdog (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers187,951 edits we don't use the word "patients".Next edit → | ||
| Line 3: | Line 3: | ||
| There is no good evidence that "young blood" has any medicinal effect in people and all blood transfusions have risks, including ]s.<ref name=sbm/> As of of 2017 evidence from two large studies showed that transfusion of blood from younger donors was either no different from, or led to ''worse'' outcomes than, blood from older donors.<ref>{{cite journal|last1=Garraud|first1=O|title=Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?|journal=Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis|date=August 2017|volume=56|issue=4|pages=635-636|doi=10.1016/j.transci.2017.07.002|pmid=28780993}}</ref> Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; research had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.<ref>{{cite journal|last1=Ning|first1=S|last2=Heddle|first2=NM|last3=Acker|first3=JP|title=Exploring donor and product factors and their impact on red cell post-transfusion outcomes.|journal=Transfusion medicine reviews|date=January 2018|volume=32|issue=1|pages=28-35|doi=10.1016/j.tmrv.2017.07.006|pmid=28988603}}</ref> | There is no good evidence that "young blood" has any medicinal effect in people and all blood transfusions have risks, including ]s.<ref name=sbm/> As of of 2017 evidence from two large studies showed that transfusion of blood from younger donors was either no different from, or led to ''worse'' outcomes than, blood from older donors.<ref>{{cite journal|last1=Garraud|first1=O|title=Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?|journal=Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis|date=August 2017|volume=56|issue=4|pages=635-636|doi=10.1016/j.transci.2017.07.002|pmid=28780993}}</ref> Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; research had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.<ref>{{cite journal|last1=Ning|first1=S|last2=Heddle|first2=NM|last3=Acker|first3=JP|title=Exploring donor and product factors and their impact on red cell post-transfusion outcomes.|journal=Transfusion medicine reviews|date=January 2018|volume=32|issue=1|pages=28-35|doi=10.1016/j.tmrv.2017.07.006|pmid=28988603}}</ref> | ||
| Alkahest, a company spun out of Stanford University's research on blood transfusion research in rodents, is collaborating with ] to create a ]-based experimental ] drug, which they propose to test in |
Alkahest, a company spun out of Stanford University's research on blood transfusion research in rodents, is collaborating with ] to create a ]-based experimental ] drug, which they propose to test in people with Alzheimer's.<ref name=Trends2017>{{cite journal|last1=de Magalhães|first1=JP|last2=Stevens|first2=M|last3=Thornton|first3=D|title=The Business of Anti-Aging Science.|journal=Trends in biotechnology|date=November 2017|volume=35|issue=11|pages=1062-1073|doi=10.1016/j.tibtech.2017.07.004|pmid=28778607}} {{open access}}</ref> Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; research had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.<ref>{{cite journal|last1=Ning|first1=S|last2=Heddle|first2=NM|last3=Acker|first3=JP|title=Exploring donor and product factors and their impact on red cell post-transfusion outcomes.|journal=Transfusion medicine reviews|date=January 2018|volume=32|issue=1|pages=28-35|doi=10.1016/j.tmrv.2017.07.006|pmid=28988603}}</ref><ref name=Trends2017>{{cite journal|last1=de Magalhães|first1=JP|last2=Stevens|first2=M|last3=Thornton|first3=D|title=The Business of Anti-Aging Science.|journal=Trends in biotechnology|date=November 2017|volume=35|issue=11|pages=1062-1073|doi=10.1016/j.tibtech.2017.07.004|pmid=28778607}} {{open access}}</ref><ref>{{cite journal|last1=Drew|first1=L|title=Neuroscience: The power of plasma|journal=Nature|date=27 September 2017|volume=549|issue=7673|pages=S26-S27|doi=10.1038/549S26a|pmid=28953857}}</ref> | ||
| Ambrosia is a company that sells what it calls "young blood transfusions" for $8,000 under the guise of running a ] to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/> ] is an investor in Ambrosia; ] was a fad in ] starting in the 2000s.<ref name="Inc">{{cite news|url=https://www.inc.com/jeff-bercovici/peter-thiel-young-blood.html|title=Peter Thiel Is Very, Very Interested In Young People's Blood|surname=Bercovici|first=Jeff|work=Inc|date=1 August 2016}}</ref><ref name="MIT17">{{cite news|url=https://www.technologyreview.com/s/603242/questionable-young-blood-transfusions-offered-in-us-as-anti-aging-remedy/|title=Questionable "Young Blood" Transfusions Offered in U.S. as Anti-Aging Remedy|publisher=MIT Technology Review |last=Maxmen |first=Amy |date=13 January 2017}}</ref> | Ambrosia is a company that sells what it calls "young blood transfusions" for $8,000 under the guise of running a ] to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/> ] is an investor in Ambrosia; ] was a fad in ] starting in the 2000s.<ref name="Inc">{{cite news|url=https://www.inc.com/jeff-bercovici/peter-thiel-young-blood.html|title=Peter Thiel Is Very, Very Interested In Young People's Blood|surname=Bercovici|first=Jeff|work=Inc|date=1 August 2016}}</ref><ref name="MIT17">{{cite news|url=https://www.technologyreview.com/s/603242/questionable-young-blood-transfusions-offered-in-us-as-anti-aging-remedy/|title=Questionable "Young Blood" Transfusions Offered in U.S. as Anti-Aging Remedy|publisher=MIT Technology Review |last=Maxmen |first=Amy |date=13 January 2017}}</ref> | ||
Revision as of 23:20, 22 May 2018
Young blood transfusion refers to the transfer of blood taken from a young person into an older person with the intention of having a medicinal effect beyond that of a normal blood transfusion.
There is no good evidence that "young blood" has any medicinal effect in people and all blood transfusions have risks, including blood-borne diseases. As of of 2017 evidence from two large studies showed that transfusion of blood from younger donors was either no different from, or led to worse outcomes than, blood from older donors. Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; research had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.
Alkahest, a company spun out of Stanford University's research on blood transfusion research in rodents, is collaborating with Grifols to create a blood plasma-based experimental biologic drug, which they propose to test in people with Alzheimer's. Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; research had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.
Ambrosia is a company that sells what it calls "young blood transfusions" for $8,000 under the guise of running a clinical trial to see if such transfusions lead to changes in the blood of recipients. Peter Thiel is an investor in Ambrosia; regenerative medicine was a fad in Silicon Valley starting in the 2000s.
References
- ^ Novella, Steven (3 August 2016). "Parabiosis – The Next Snakeoil". Science-Based Medicine.
- Garraud, O (August 2017). "Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?". Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 56 (4): 635–636. doi:10.1016/j.transci.2017.07.002. PMID 28780993.
- Ning, S; Heddle, NM; Acker, JP (January 2018). "Exploring donor and product factors and their impact on red cell post-transfusion outcomes". Transfusion medicine reviews. 32 (1): 28–35. doi:10.1016/j.tmrv.2017.07.006. PMID 28988603.
- ^ de Magalhães, JP; Stevens, M; Thornton, D (November 2017). "The Business of Anti-Aging Science". Trends in biotechnology. 35 (11): 1062–1073. doi:10.1016/j.tibtech.2017.07.004. PMID 28778607.
- Ning, S; Heddle, NM; Acker, JP (January 2018). "Exploring donor and product factors and their impact on red cell post-transfusion outcomes". Transfusion medicine reviews. 32 (1): 28–35. doi:10.1016/j.tmrv.2017.07.006. PMID 28988603.
- Drew, L (27 September 2017). "Neuroscience: The power of plasma". Nature. 549 (7673): S26 – S27. doi:10.1038/549S26a. PMID 28953857.
- Bercovici, Jeff (1 August 2016). "Peter Thiel Is Very, Very Interested In Young People's Blood". Inc.
- Maxmen, Amy (13 January 2017). "Questionable "Young Blood" Transfusions Offered in U.S. as Anti-Aging Remedy". MIT Technology Review.